Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Signatures

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    119 result(s) found for: Signatures. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2010-018559-84 Sponsor Protocol Number: AMB-WEI-1052-I Start Date*: 2010-07-20
    Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen
    Full Title: AMBITIOUS Atopic Dermatitis Biomarker Identification Trial in Omalizumab Usage Single- arm trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment i...
    Medical condition: AMBITIOUS is a trial to identify potential markers underlying variability in response to Omalizumab (Xolair®) treatment in atopic dermatitis Atopische Dermatitis is a common inflammatory skin disea...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10029264 Neurodermatitis aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004013-94 Sponsor Protocol Number: MO22004 Start Date*: 2009-12-10
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A prospective Phase II study to evaluate alterations in molecular biomarkers in HER2-positive metastatic breast cancer together with assessment of trastuzumab use beyond progression after initial e...
    Medical condition: Treatment of patients with HER2-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000815-15 Sponsor Protocol Number: BOS-1168-WEI-0080-I Start Date*: 2011-08-02
    Sponsor Name:Medizinische Fakultät der technischen Universität Muenchen
    Full Title: BOSTRIP (Investigator Initiated Trial) (Biomarkers of systemic treatment response in Psoriasis) Differential analysis of metabolomic profiles in patients with chronic plaque psoriasis underg...
    Medical condition: Psoriasis is a chronic hyperproliferative and inflammatory skin disease with its major subtype, chronic plaque-type psoriasis, affecting approximately 2% of individuals in Western populations. It m...
    Disease:
    Population Age: Elderly Gender:
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003462-40 Sponsor Protocol Number: 18IC07 Start Date*: 2020-03-30
    Sponsor Name:Great Ormond Street Hospital for Children NHS Trust
    Full Title: Phase 1 , open label study of CRISPR-CAR genome edited T cells (TT52CAR19) in relapsed /refractory B Cell Acute Lymphoblastic Leukaemia
    Medical condition: Relapsed/ refractory B- cell acute lymphoid leukaemia
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-004487-25 Sponsor Protocol Number: KETASELF-1 Start Date*: 2021-02-08
    Sponsor Name:Linköpings Universitet
    Full Title: Experiencing the self through touch - self-other-distinction in an altered state of self: An exploratory randomized placebo-controlled experimental medicine study
    Medical condition: Healthy volunteer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002031-92 Sponsor Protocol Number: EX0307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otto-von-Guericke University
    Full Title: Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.
    Medical condition: Dyspeptic Symptoms GERD (gastroesophageal reflux disease), NERD (non erosive reflux disease), ERD (erosive reflux disease), Barretts esophagus, Adeno-CA of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017885 Gastrooesophageal reflux disease PT
    9.1 10004137 Barrett's oesophagus PT
    9.1 10001173 Adenocarcinoma of esophagus LLT
    9.1 10013949 Dyspeptic signs and symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000889-38 Sponsor Protocol Number: 2019/MyJIA Start Date*: 2020-09-16
    Sponsor Name:Oslo University Hospital
    Full Title: Strategies towards personalised treatment in Juvenile Idiopathic Arthritis (JIA): An open randomised multicentre blinded-assessor trial assessing the effectiveness of intra-articular glucocortico...
    Medical condition: Juvenile idiopathic arthritis is characterised by inflamed joints and is the most common chronic rheumatic disease in childhood and adolescence that potentially lead to disability due to joint dama...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002535-28 Sponsor Protocol Number: R4-RA Start Date*: 2013-01-21
    Sponsor Name:Joint Research & Development Office (Barts and The London School of Medicine & Dentistry)
    Full Title: A Randomised, open labelled study in anti-TNFa inadequate responders to investigate the mechanisms for Response - Resistance to Rituximab versus Tocilizumab in RA (R4-RA)
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) BE (Completed) IT (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005346-58 Sponsor Protocol Number: RIMINI Start Date*: 2016-10-05
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI)
    Medical condition: Rejection rate, graft loss or poor graft function defined as eGFR<40 ml/min in patients with kidney transplantation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-005371-34 Sponsor Protocol Number: 2 39 00240 133 Start Date*: 2008-03-18
    Sponsor Name:BEAUFOUR IPSEN PHARMA
    Full Title: EFFICACY OF EGb 761® 120 mg bid VERSUS PLACEBO IN PATIENTS SUFFERING FROM FRIEDREICH ATAXIA A 3 months, phase II, randomised, double blind, placebo-controlled, parallel groups, clinical study.
    Medical condition: Out patient suffering from friedreich ataxia aged from 12 to 20 years
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001508-13 Sponsor Protocol Number: COL-CHIPHF-P24 Start Date*: 2021-08-06
    Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt
    Full Title: Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular...
    Medical condition: Ischemic heart failure with reduced ejection fraction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002701-11 Sponsor Protocol Number: ACE Start Date*: 2016-06-13
    Sponsor Name:Oslo University Hospital
    Full Title: ADJUVANT CHEMOTHERAPY IN ELDERLY – GERIATRIC ASSESSMENT AND PROGNOSTIC GENE SIGNATURES
    Medical condition: undergone R0-resection of for colon cancer stage III
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005860-24 Sponsor Protocol Number: OmniaOMS Start Date*: 2022-10-28
    Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA
    Full Title: Multidimensional integrated assessment of neurological and immunological patterns to test the efficacy and response to Ozanimod in multiple sclerosis
    Medical condition: relapsing remitting multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004695-35 Sponsor Protocol Number: CA209-8Y8 Start Date*: 2019-06-10
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- ...
    Medical condition: Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) CZ (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) PT (Completed) GR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-005278-40 Sponsor Protocol Number: ABR-55752 Start Date*: 2016-11-29
    Sponsor Name:Radboudumc
    Full Title: Molecular imaging before and during (chemo-) radiotherapy in patients with locally advanced Head and Neck, thoracic and pelvic tumors: prognostic and predictive value of 18F-fluoroazomycin arabinos...
    Medical condition: Head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004223-16 Sponsor Protocol Number: PEBBLE Start Date*: 2021-05-10
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II study investigating preoperative bintrafusp alfa in operable urothelial carcinoma of the bladder.
    Medical condition: Urothelial carcinoma requiring radical cystectomy with bilateral pelvic lymph node dissection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001984-35 Sponsor Protocol Number: M16OPN Start Date*: 2017-06-22
    Sponsor Name:Antoni van leeuwenhoek ziekenhuis
    Full Title: Multicenter Phase 2 Study to Identify of the Optimal neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)
    Medical condition: Patients with stage III melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing) AT (Prematurely Ended) GB (GB - no longer in EU/EEA) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001453-31 Sponsor Protocol Number: CONMED3 Start Date*: Information not available in EudraCT
    Sponsor Name:Copenhagen University Hospital Rigshospitalet
    Full Title: Automated pupillometry and NIRS-EEG to detect signatures of consciousness in acute brain injury after apomorphine and methylphenidate stimulation: A placebo-controlled, randomized, cross-over study
    Medical condition: We investigate the possible effects of commercially available apomorphine and methylphenidate on signatures of consciousness in patients admitted to the ICU with acute disorder of consciousness, us...
    Disease: Version SOC Term Classification Code Term Level
    25.1 10029205 - Nervous system disorders 10013509 Disturbances in consciousness NEC HLT
    21.1 10029205 - Nervous system disorders 10067967 Brain injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004079-30 Sponsor Protocol Number: STRAP_ReDA_012206 Start Date*: 2018-02-19
    Sponsor Name:Joint Research & Development Office (QMUL)
    Full Title: Stratification of Biologic Therapies for RA by Pathobiology (STRAP)-EU: A randomised, open-labelled biopsy-driven stratification trial in DMARD inadequate responder patients randomised to Etanercep...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-006958-31 Sponsor Protocol Number: 2021/3401 Start Date*: 2022-05-24
    Sponsor Name:Gustave Roussy
    Full Title: An Interventional and Translational Study investigating Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C
    Medical condition: Locally-advanced and unresectable or metastatic non-small-cell lung cancer with KRAS G12C mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 20:57:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA